Skip to main content
SpringerLink
Log in
Book cover

Skin Tumors and Reactions to Cancer Therapy in Children pp 101–137Cite as

Cutaneous Reactions to Traditional Chemotherapy and Radiation Therapy

  • Chapter
  • First Online:

Abstract

Pediatric oncology patients can present with a variety of cutaneous findings, oftentimes related to administered chemotherapeutic agents. Toxic effects of chemotherapy on the skin, hair, nails, and mucous membranes are common, but not well described in children. Early recognition of cutaneous side effects of chemotherapy both by oncologists and dermatologists can aid in diagnosis and management of these conditions, to allow for complete care of cancer patients. This chapter discusses different classes of chemotherapeutic agents, their mechanisms of action, and their uses in specific malignancies. Acute cutaneous side effects of traditional chemotherapeutic agents are discussed in detail. Radiation therapy is also discussed, as well as its immediate effect on the skin, hair, mucous membranes, and nails and strategies for management.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Bolognia JL, Cooper DL, Glusac EJ. Toxic erythema of chemotherapy: a useful clinical term. J Am Acad Dermatol. 2008;59(3):524–9.

    Article  PubMed  Google Scholar 

  2. Wanat KA, Bandow GD, Klekotka PA. Palmar-plantar erythrodysesthesia caused by mercaptopurine and mesalamine. Arch Dermatol. 2008;144(8):1079–81.

    Article  PubMed  Google Scholar 

  3. Cox GJ, Robertson DB. Toxic erythema of palms and soles associated with high-dose mercaptopurine chemotherapy. Arch Dermatol. 1986;122(12):1413–4.

    Article  CAS  PubMed  Google Scholar 

  4. Giacchero D, Monpoux F, Chiaverini C, Lacour JP. Syndrome mains-pieds secondaire a la prise de 6-mercaptopurine chez un enfant de quatre ans [6-mercaptopurine-related hand-foot syndrome in a four-year-old child]. Ann Dermatol Venereol. 2008;135(8–9):580–3 (in French).

    Google Scholar 

  5. Bouhnik Y, Lemann M, Mary JY, Scemama G, Tai R, Matuchansky C, et al. Long-term follow-up of patients with Crohn’s disease treated with azathioprine or 6-mercaptopurine. Lancet. 1996;347(8996):215–9.

    Article  CAS  PubMed  Google Scholar 

  6. Disanti W, Rajapakse RO, Korelitz BI, Panagopoulos G, Bratcher J. Incidence of neoplasms in patients who develop sustained leukopenia during or after treatment with 6-mercaptopurine for inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006;4(8):1025–9.

    Article  CAS  PubMed  Google Scholar 

  7. Schmiegelow K, Al-Modhwahi I, Andersen MK, Behrendtz M, Forestier E, Hasle H, et al. Methotrexate/6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study. Blood. 2009;113(24):6077–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Setshedi M, Epstein D, Winter TA, Myer L, Watermeyer G, Hift R. Use of thiopurines in the treatment of inflammatory bowel disease is associated with an increased risk of non-melanoma skin cancer in an at-risk population: a cohort study. J Gastroenterol Hepatol. 2012;27(2):385–9. Epub 2011/07/29 (in English)

    Article  CAS  PubMed  Google Scholar 

  9. Subramaniam K, Pavli P. Risk of non-melanoma skin cancer with thiopurine use in inflammatory bowel disease. J Gastroenterol Hepatol. 2012;27(2):193–4.

    Article  CAS  PubMed  Google Scholar 

  10. Binder B, Ahlgrimm-Siess V, Hofmann-Wellenhof R. Eruptive melanozytare Navi palmoplantar bei einer Patientin mit M.Crohn [Eruptive melanocytic nevi of the palms and soles in a patient with Crohn disease]. J Dtsch Dermatol Ges. 2006;4(6):486–8. PubMed PMID: 16734838. Epub 2006/06/01 (in German).

    Google Scholar 

  11. Bovenschen HJ, Tjioe M, Vermaat H, de Hoop D, Witteman BM, Janssens RW, et al. Induction of eruptive benign melanocytic naevi by immune suppressive agents, including biologicals. Br J Dermatol. 2006;154(5):880–4.

    Article  CAS  PubMed  Google Scholar 

  12. Braun SA, Helbig D, Frank J, Hanneken S. Eruptive melanozytare Navi unter Behandlung einer Myasthenia gravis mit Azathioprin [Eruptive melanocytic nevi during azathioprine therapy in myasthenia gravis]. Hautarzt. 2012;63(10):756–9. Epub 2012/09/26 (in German).

    Google Scholar 

  13. de Boer NK, Kuyvenhoven JP. Eruptive benign melanocytic naevi during immunosuppressive therapy in a Crohn’s disease patient. Inflamm Bowel Dis 2011;17(6):E26.

    Google Scholar 

  14. Perry BM, Nguyen A, Desmond BL, Blattner CM, Thomas RS, Young RJ. Eruptive nevi associated with medications (ENAMs). J Am Acad Dermatol. 2016;75(5):1045–52.

    Article  PubMed  Google Scholar 

  15. Wonders J, De Boer NK, Van Weyenberg SJ. Spot diagnosis: eruptive melanocytic naevi during azathioprine therapy in Crohn’s disease. J Crohns Colitis. 2012;6(5):636.

    Article  PubMed  Google Scholar 

  16. Woodhouse J, Maytin EV. Eruptive nevi of the palms and soles. J Am Acad Dermatol. 2005;52(5 Suppl 1):S96–S100.

    Article  PubMed  Google Scholar 

  17. Reutter JC, Long EM, Morrell DS, Thomas NE, Groben PA. Eruptive post-chemotherapy in situ melanomas and dysplastic nevi. Pediatr Dermatol. 2007;24(2):135–7.

    Article  PubMed  Google Scholar 

  18. Baird EA, McHenry PM, MacKie RM. Effect of maintenance chemotherapy in childhood on numbers of melanocytic naevi. BMJ. 1992;305(6857):799–801.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. de Wit PE, de Vaan GA, de Boo TM, Lemmens WA, Rampen FH. Prevalence of naevocytic naevi after chemotherapy for childhood cancer. Med Pediatr Oncol. 1990;18(4):336–8.

    Article  PubMed  Google Scholar 

  20. Hughes BR, Cunliffe WJ, Bailey CC. Excess benign melanocytic naevi after chemotherapy for malignancy in childhood. BMJ. 1989;299(6691):88–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Bazarbachi A, Bachelez H, Dehen L, Delmer A, Zittoun R, Dubertret L. Lethal paraneoplastic pemphigus following treatment of chronic lymphocytic leukaemia with fludarabine. Ann Oncol. 1995;6(7):730–1.

    Article  CAS  PubMed  Google Scholar 

  22. Gooptu C, Littlewood TJ, Frith P, Lyon CC, Carmichael AJ, Oliwiecki S, et al. Paraneoplastic pemphigus: an association with fludarabine? Br J Dermatol. 2001;144(6):1255–61.

    Article  CAS  PubMed  Google Scholar 

  23. Powell AM, Albert S, Oyama N, Sakuma-Oyama Y, Bhogal B, Black MM. Paraneoplastic pemphigus secondary to fludarabine evolving into unusual oral pemphigus vegetans. J Eur Acad Dermatol Venereol. 2004;18(3):360–4.

    Article  CAS  PubMed  Google Scholar 

  24. Yildiz O, Ozguroglu M, Yanmaz MT, Turna H, Kursunoglu SG, Antonov M, et al. Paraneoplastic pemphigus associated with fludarabine use. Med Oncol. 2007;24(1):115–8.

    Article  PubMed  Google Scholar 

  25. Perera GK, Devereux S, Mufti G, Salisbury J, Creamer D. PNP with Waldenstrom’s macroglobulinaemia. Clin Exp Dermatol. 2005;30(1):27–9.

    Article  CAS  PubMed  Google Scholar 

  26. Parker TL, Cooper DL, Seropian SE, Bolognia JL. Toxic erythema of chemotherapy following i.v. BU plus fludarabine for allogeneic PBSC transplant. Bone Marrow Transplant. 2013;48(5):646–50.

    Article  CAS  PubMed  Google Scholar 

  27. Briones J, Pereira A, Alcorta I. Transfusion-associated graft-versus-host disease (TA-GVHD) in fludarabine-treated patients: is it time to irradiate blood component? Br J Haematol. 1996;93(3):739–41. Epub 1996/06/01 (in English)

    CAS  PubMed  Google Scholar 

  28. Briz M, Cabrera R, Sanjuan I, Fores R, Diez JL, Herrero M, et al. Diagnosis of transfusion-associated graft-versus-host disease by polymerase chain reaction in fludarabine-treated B-chronic lymphocytic leukaemia. Br J Haematol. 1995;91(2):409–11.

    Article  CAS  PubMed  Google Scholar 

  29. Leitman SF, Tisdale JF, Bolan CD, Popovsky MA, Klippel JH, Balow JE, et al. Transfusion-associated GVHD after fludarabine therapy in a patient with systemic lupus erythematosus. Transfusion (Paris). 2003;43(12):1667–71.

    Article  Google Scholar 

  30. Maung ZT, Wood AC, Jackson GH, Turner GE, Appleton AL, Hamilton PJ. Transfusion-associated graft-versus-host disease in fludarabine-treated B-chronic lymphocytic leukaemia. Br J Haematol. 1994;88(3):649–52.

    Article  CAS  PubMed  Google Scholar 

  31. Williamson LM, Wimperis JZ, Wood ME, Woodcock B. Fludarabine treatment and transfusion-associated graft-versus-host disease. Lancet. 1996;348(9025):472–3.

    Article  CAS  PubMed  Google Scholar 

  32. Anderson KC, Weinstein HJ. Transfusion-associated graft-versus-host disease. N Engl J Med. 1990;323:315–21.

    Article  CAS  PubMed  Google Scholar 

  33. Rashid K, Ng R, Mastan A, Sager D, Hirschman R. Accelerated growth of skin carcinoma following fludarabine therapy for chronic lymphocytic leukemia. Leuk Lymphoma. 2005;46(7):1051–5.

    Article  CAS  PubMed  Google Scholar 

  34. Davidovitz Y, Ballin A, Meytes D. Flare-up of squamous cell carcinoma of the skin following fludarabine therapy for chronic lymphocytic leukemia. Acta Haematol. 1997;98(1):44–6.

    Article  CAS  PubMed  Google Scholar 

  35. Herr D, Borelli S, Kempf W, Trojan A. Fludarabine: risk factor for aggressive behaviour of squamous cell carcinoma of the skin? Ann Oncol. 2005;16(3):515–6.

    Article  CAS  PubMed  Google Scholar 

  36. Grey MR, Flanagan NG, Kelsey PR. Severe skin rash in two consecutive patients treated with 2-chlorodeoxyadenosine for hairy cell leukaemia at a single institution. Clin Lab Haematol. 2000;22(2):111–3.

    Article  CAS  PubMed  Google Scholar 

  37. Hendrick A. Purpuric rash following treatment with 2-chlorodeoxyadenosine. Clin Lab Haematol. 2001;23(1):67–8.

    Article  CAS  PubMed  Google Scholar 

  38. Rossini MS, de Souza EM, Cintra ML, Pagnano KB, Chiari AC, Lorand-Metze I. Cutaneous adverse reaction to 2-chlorodeoxyadenosine with histological flame figures in patients with chronic lymphocytic leukaemia. J Eur Acad Dermatol Venereol. 2004;18(5):538–42.

    Article  CAS  PubMed  Google Scholar 

  39. Meunier P, Castaigne S, Bastie JN, Chosidow O, Aractingi S. Cutaneous reactions after treatment with 2-chlorodeoxyadenosine. Acta Derm Venereol. 1996;76(5):385–6.

    CAS  PubMed  Google Scholar 

  40. Larfars G, Uden-Blohme AM, Samuelsson J. Fludarabine, as well as 2-chlorodeoxyadenosine, can induce eosinophilia during treatment of lymphoid malignancies. Br J Haematol. 1996;94(4):709–12.

    Article  CAS  PubMed  Google Scholar 

  41. Robak T, Blasinska-Morawiec M, Krykowski E. Transient eosinophilia in a patient with hairy-cell leukaemia treated with 2-chlorodeoxyadenosine. Acta Haematol Pol. 1992;23(4):285–90.

    CAS  PubMed  Google Scholar 

  42. Robak T, Blasinska-Morawiec M, Krykowski E, Hellmann A, Lewandowski K, Dmoszynska A, et al. 2-Chlorodeoxyadenosine (cladribine)-related eosinophilia in patients with lymphoproliferative diseases. Eur J Haematol. 1997;59(4):216–20.

    Article  CAS  PubMed  Google Scholar 

  43. Robak T, Sysa-Jedrzejowska A, Robak E, Dabkowski J, Blasinska-Morawiec M. 2-Chlorodeoxyadenosine (cladribine) induced allergic cutaneous reactions with eosinophilia in a patient with B-cell chronic lymphocytic leukemia. J Med. 1997;28(3–4):199–209.

    CAS  PubMed  Google Scholar 

  44. Rutella S, Sica S, Rumi C, Martucci R, Etuk B, De Stefano V, et al. Hypereosinophilia during 2-chlorodeoxyadenosine treatment for hairy cell leukaemia. Br J Haematol. 1996;92(2):426–8.

    Article  CAS  PubMed  Google Scholar 

  45. Zulian GB, Roux E, Tiercy JM, Extermann M, Diebold-Berger S, Reymond JM, et al. Transfusion-associated graft-versus-host disease in a patient treated with Cladribine (2-chlorodeoxyadenosine): demonstration of exogenous DNA in various tissue extracts by PCR analysis. Br J Haematol. 1995;89(1):83–9.

    Google Scholar 

  46. Zevin S, Hershko C, Rosenmann E. Halogenoderma of the forearm caused by 2-chlorodeoxyadenosine treatment. Am J Hematol. 1996;53(3):209–10.

    Article  CAS  PubMed  Google Scholar 

  47. Disel U, Gurkut O, Abali H, Kaleagasi H, Mertsoylu H, Ozyilkan O, et al. Unilateral hand-foot syndrome: an extraordinary side effect of capecitabine. Cutan Ocul Toxicol. 2010;29(2):140–2.

    Article  CAS  PubMed  Google Scholar 

  48. Kigen G, Busakhala N, Njiru E, Chite F, Loehrer P. Palmar-plantar erythrodysesthesia associated with capecitabine chemotherapy: a case report. Pan Afr Med J. 2015;21:228.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Lal HS. Hand and foot syndrome secondary to capecitabine. Indian J Dermatol Venereol Leprol. 2014;80(5):427–30.

    Article  PubMed  Google Scholar 

  50. Matsuda S, Koketsu H, Hayakawa M, Nagata N. Unilateral capecitabine-related hand-foot syndrome. Intern Med. 2015;54(21):2779.

    Article  CAS  PubMed  Google Scholar 

  51. Surjushe A, Vasani R, Medhekar S, Thakre M, Saple DG. Hand-foot syndrome due to capecitabine. Indian J Dermatol. 2009;54(3):301–2.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Matsuyama T, Uetake H, Aoyagi H, Kobayashi H, Ishikawa T, Iida S, et al. A case report of a patient with hand-foot syndrome induced by bolus 5-fluorouracil therapy. Gan To Kagaku Ryoho. 2008;35(12):2147–9.

    PubMed  Google Scholar 

  53. Chiara S, Nobile MT, Barzacchi C, Sanguineti O, Vincenti M, Di Somma C, et al. Hand-foot syndrome induced by high-dose, short-term, continuous 5-fluorouracil infusion. Eur J Cancer. 1997;33(6):967–9.

    Article  CAS  PubMed  Google Scholar 

  54. NCI Common Terminology Criteria for Adverse Events (CTCAE) v4. National Cancer Institute, National Institutes of Health, U.S. Department of Health and Human Services, Bethesda, MD.

    Google Scholar 

  55. Fernandes NF, Rosenbach M, Elenitsas R, Kist JM. Subacute cutaneous lupus erythematosus associated with capecitabine monotherapy. Arch Dermatol. 2009;145(3):340–1.

    Article  PubMed  Google Scholar 

  56. Floristan U, Feltes RA, Sendagorta E, Feito-Rodriguez M, Ramirez-Marin P, Vidaurrazaga C, et al. Subacute cutaneous lupus erythematosus induced by capecitabine. Clin Exp Dermatol. 2009;34(7):e328–9.

    Article  CAS  PubMed  Google Scholar 

  57. Fongue J, Meunier B, Lardet D, Dicostanzo MP, Rouby F, Terrier JP, et al. Capecitabine-induced subacute cutaneous lupus: a case report. Ann Dermatol Venereol. 2014;141(10):593–7.

    Article  CAS  PubMed  Google Scholar 

  58. Kim WI, Kim JM, Kim GW, Mun JH, Song M, Kim HS, et al. Subacute cutaneous lupus erythematosus induced by capecitabine: 5-FU was innocent. J Eur Acad Dermatol Venereol. 2016;30(11):e163–e4.

    CAS  PubMed  Google Scholar 

  59. Kindem S, Llombart B, Requena C, Ruiz A, Traves V, Guillen C, et al. Subacute cutaneous lupus erythematosus after treatment with capecitabine. J Dermatol. 2013;40(1):75–6.

    Article  PubMed  Google Scholar 

  60. Ko JH, Hsieh CI, Chou CY, Wang KH. Capecitabine-induced subacute cutaneous lupus erythematosus: report of a case with positive rechallenge test. J Dermatol. 2013;40(11):939–40.

    Article  PubMed  Google Scholar 

  61. Li Z, Jiang N, Xu Y. The concurrence of subacute cutaneous lupus erythematosus and hand-foot syndrome in a patient undergoing capecitabine chemotherapy. Australas J Dermatol. 2016;57(1):e14–6.

    Article  PubMed  Google Scholar 

  62. Merlin F, Prochilo T, Kildani B, Lombardi C, Pasolini G, Bonetti F, et al. Discoid lupus erythematosus (DLE)-like lesions induced by capecitabine. Int J Colorectal Dis. 2008;23(7):715–6.

    Article  CAS  PubMed  Google Scholar 

  63. Ozaslan E, Eroglu E, Gok K, Senel S, Baldane S, Akyol L, et al. Drug induced lupus erythematosus due to capecitabine and bevacizumab treatment presenting with prolonged thrombocytopenia. Rom J Intern Med. 2015;53(3):282–5.

    PubMed  Google Scholar 

  64. Weger W, Kranke B, Gerger A, Salmhofer W, Aberer E. Occurrence of subacute cutaneous lupus erythematosus after treatment with fluorouracil and capecitabine. J Am Acad Dermatol. 2008;59(2 Suppl 1):S4–6.

    Article  PubMed  Google Scholar 

  65. Wiesenthal A, Matherne R, Gibson B. Capecitabine-induced systemic lupus erythematosus and palmoplantar erythrodysesthesia. J Drugs Dermatol. 2012;11(6):769–71.

    PubMed  Google Scholar 

  66. Al-Ahwal MS. Chemotherapy and fingerprint loss: beyond cosmetic. Oncologist. 2012;17(2):291–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Chavarri-Guerra Y, Soto-Perez-de-Celis E. Images in clinical medicine. Loss of fingerprints. N Engl J Med. 2015;372(16):e22.

    Article  PubMed  CAS  Google Scholar 

  68. van Doorn L, Veelenturf S, Binkhorst L, Bins S, Mathijssen R. Capecitabine and the risk of fingerprint loss. JAMA Oncol. 2017;3(1):122–3.

    Article  PubMed  Google Scholar 

  69. Wong M, Choo SP, Tan EH. Travel warning with capecitabine. Ann Oncol. 2009;20(7):1281.

    Article  CAS  PubMed  Google Scholar 

  70. Lee SD, Kim HJ, Hwang SJ, Kim YJ, Nam SH, Kim BS. Hand-foot syndrome with scleroderma-like change induced by the oral capecitabine: a case report. Korean J Intern Med. 2007;22(2):109–12.

    Article  PubMed  PubMed Central  Google Scholar 

  71. Trindade F, Haro R, Farina MC, Requena L. Hand-foot syndrome with sclerodactyly-like changes in a patient treated with capecitabine. Am J Dermatopathol. 2008;30(2):172–3.

    Article  PubMed  Google Scholar 

  72. Saif MW, Agarwal A, Hellinger J, Park DJ, Volkmann E. Scleroderma in a Patient on Capecitabine: Is this a Variant of Hand-Foot Syndrome? Cureus. 2016;8(6):e663.

    PubMed  PubMed Central  Google Scholar 

  73. O’Doherty CS. Letter: Hyperpigmentation after cancer chemotherapy. Lancet. 1975;2(7930):365–6.

    Article  PubMed  Google Scholar 

  74. Hrushesky WJ. Letter: Serpentine supravenous fluorouracil hyperpigmentation. JAMA. 1976;236(2):138.

    Article  CAS  PubMed  Google Scholar 

  75. Pujol RM, Rocamora V, Lopez-Pousa A, Taberner R, Alomar A. Persistent supravenous erythematous eruption: a rare local complication of intravenous 5-fluorouracil therapy. J Am Acad Dermatol. 1998;39(5 Pt 2):839–42.

    Article  CAS  PubMed  Google Scholar 

  76. Vukelja SJ, Bonner MW, McCollough M, Cobb PW, Gaule DA, Fanucchi PJ, et al. Unusual serpentine hyperpigmentation associated with 5-fluorouracil. Case report and review of cutaneous manifestations associated with systemic 5-fluorouracil. J Am Acad Dermatol. 1991;25(5 Pt 2):905–8.

    Article  CAS  PubMed  Google Scholar 

  77. Suvirya S, Agrawal A, Parihar A. 5-Fluorouracil-induced bilateral persistent serpentine supravenous hyperpigmented eruption, bilateral mottling of palms and diffuse hyperpigmentation of soles. BMJ Case Rep. 2014;2014.

    Google Scholar 

  78. Allen BJ, Parker D, Wright AL. Reticulate pigmentation due to 5-fluorouracil. Int J Dermatol. 1995;34(3):219–20.

    Article  CAS  PubMed  Google Scholar 

  79. Jogi R, Garman M, Pielop J, Orengo I, Hsu S. Reticulate Hyperpigmentation secondary to 5-fluorouracil and idarubicin. J Drugs Dermatol. 2005;4(5):652–6.

    PubMed  Google Scholar 

  80. Masson Regnault M, Gadaud N, Boulinguez S, Tournier E, Lamant L, Gladieff L, et al. Chemotherapy-related reticulate hyperpigmentation: a case series and review of the literature. Dermatology. 2015;231(4):312–8.

    Article  CAS  PubMed  Google Scholar 

  81. Paravar T, Hymes SR. Longitudinal melanonychia induced by capecitabine. Dermatol Online J. 2009;15(10):11.

    PubMed  Google Scholar 

  82. Hogeling M, Howard J, Kanigsberg N, Finkelstein H. Onycholysis associated with capecitabine in patients with breast cancer. J Cutan Med Surg. 2008;12(2):93–5.

    Article  PubMed  Google Scholar 

  83. Tejera A, Bosch RJ, Lopez N, Herrera E. Onicolisis con exudado del hiponiquio secundaria a quimioterapia con paclitaxel y capecitabina [Onycholysis with hyponychium exudate secondary to chemotherapy with paclitaxel and capecitabine]. Actas Dermosifiliogr. 2006;97(8):536–8.

    Google Scholar 

  84. Maino KL, Norwood C, Stashower ME. Onycholysis with the appearance of a “sunset” secondary to capecitabine. Cutis. 2003;72(3):234–6.

    PubMed  Google Scholar 

  85. Munoz A, Barcelo R, Rubio I, Mane JM, Ferreiro J, Lopez-Vivanco G. Onycholysis associated with capecitabine in combination with irinotecan in two patients with colorectal cancer. J Natl Cancer Inst. 2003;95(16):1252–3.

    Article  PubMed  Google Scholar 

  86. Chen GY, Chen YH, Hsu MM, Tsao CJ, Chen WC. Onychomadesis and onycholysis associated with capecitabine. Br J Dermatol. 2001;145(3):521–2.

    Article  CAS  PubMed  Google Scholar 

  87. Cetkovska P, Pizinger K, Cetkovsky P. High-dose cytosine arabinoside-induced cutaneous reactions. J Eur Acad Dermatol Venereol. 2002;16(5):481–5.

    Article  CAS  PubMed  Google Scholar 

  88. Aytac S, Gumruk F, Cetin M, Tuncer M, Yetgin S. Acral erythema with bullous formation: a side effect of chemotherapy in a child with acute lymphoblastic leukemia. Turk J Pediatr. 2010;52(2):211–4.

    PubMed  Google Scholar 

  89. Ozmen S, Dogru M, Bozkurt C, Kocaoglu AC. Probable cytarabine-induced acral erythema: report of 2 pediatric cases. J Pediatr Hematol Oncol. 2013;35(1):e11–3.

    Article  PubMed  Google Scholar 

  90. Anesi GL, Levine D, Attar EC, Fathi AT. Bilateral ear swelling and erythema after chemotherapy: a case of ara-C ears. J Clin Oncol. 2012;30(16):e146.

    Article  PubMed  Google Scholar 

  91. Ruben BS, Yu WY, Liu F, Truong SV, Wang KC, Fox LP. Generalized benign cutaneous reaction to cytarabine. J Am Acad Dermatol. 2015;73(5):821–8.

    Article  CAS  PubMed  Google Scholar 

  92. Figueiredo MS, Yamamoto M, Kerbauy J. Necrolise epidermica toxica secundaria ao uso da citosina-arabinosideo em dose intermediaria [Toxic epidermal necrolysis after the use of intermediate dose of cytosine arabinoside]. Rev Assoc Med Bras (1992). 1998;44(1):53–5.

    Google Scholar 

  93. Ozkan A, Apak H, Celkan T, Yuksel L, Yildiz I. Toxic epidermal necrolysis after the use of high-dose cytosine arabinoside. Pediatr Dermatol. 2001;18(1):38–40.

    Article  CAS  PubMed  Google Scholar 

  94. Bailey DL, Barron D, Lucky AW. Neutrophilic eccrine hidradenitis: a case report and review of the literature. Pediatr Dermatol. 1989;6(1):33–8.

    Article  CAS  PubMed  Google Scholar 

  95. Kanzaki H, Oono T, Makino E, Arata J, Oda M, Akazai A. Neutrophilic eccrine hidradenitis: report of two cases. J Dermatol. 1995;22(2):137–42.

    Article  CAS  PubMed  Google Scholar 

  96. Srivastava M, Scharf S, Meehan SA, Polsky D. Neutrophilic eccrine hidradenitis masquerading as facial cellulitis. J Am Acad Dermatol. 2007;56(4):693–6.

    Article  PubMed  Google Scholar 

  97. Fitzpatrick JE, Bennion SD, Reed OM, Wilson T, Reddy VV, Golitz L. Neutrophilic eccrine hidradenitis associated with induction chemotherapy. J Cutan Pathol. 1987;14(5):272–8.

    Article  CAS  PubMed  Google Scholar 

  98. Chen YM, Liu JM, Tsai CM, Whang-Peng J, Perng RP. Maculopapular rashes secondary to gemcitabine injection for non-small-cell lung cancer. J Clin Oncol. 1996;14(5):1743–4.

    Article  CAS  PubMed  Google Scholar 

  99. Dua V, Goyal H. Gemcitabine induced skin rash. Indian Pediatr. 2013;50(4):430.

    Article  PubMed  Google Scholar 

  100. Li J, Ko CJ, Saif MW. Recurrent cutaneous toxic erythema induced by gemcitabine in a patient with pancreatic cancer. Cutan Ocul Toxicol. 2009;28(3):144–8.

    Article  CAS  PubMed  Google Scholar 

  101. Asemota E, Reid E, Kovarik C. Gemcitabine-induced pseudocellulitis in a patient with non-small cell lung carcinoma. JAAD Case Rep. 2015;1(4):178–81.

    Article  PubMed  PubMed Central  Google Scholar 

  102. Curtis S, Hong S, Gucalp R, Calvo M. Gemcitabine-induced pseudocellulitis in a patient with recurrent lymphedema: a case report and review of the current literature. Am J Ther. 2016;23(1):e321–3.

    Article  PubMed  Google Scholar 

  103. Dasanu CA, Bockorny B. Recurrent pseudocellulitis due to gemcitabine: underrecognized and underreported? J Oncol Pharm Pract. 2015;21(5):377–9.

    Article  CAS  PubMed  Google Scholar 

  104. Obeid KM, Venugopal AA. Gemcitabine-associated “pseudocellulitis” and “pseudosepsis”: a case report and review of the literature. Am J Ther. 2013;20(1):118–20.

    Article  PubMed  Google Scholar 

  105. Strouse C, Epperla N. A rash diagnosis: Gemcitabine-associated pseudocellulitis. J Oncol Pharm Pract. 2017;23(2):157–60. Epub 2016 Jun 23.

    Article  PubMed  Google Scholar 

  106. Tan DH, Bunce PE, Liles WC, Gold WL. Gemcitabine-related “pseudocellulitis”: report of 2 cases and review of the literature. Clin Infect Dis. 2007;45(5):e72–6.

    Article  CAS  PubMed  Google Scholar 

  107. Brandes A, Reichmann U, Plasswilm L, Bamberg M. Time- and dose-limiting erysipeloid rash confined to areas of lymphedema following treatment with gemcitabine—a report of three cases. Anticancer Drugs. 2000;11(1):15–7.

    Article  CAS  PubMed  Google Scholar 

  108. GEMZAR® (GEMCITABINE HCL) FOR INJECTION.

    Google Scholar 

  109. Azzoli CG, Miller VA, Ng KK, Krug LM, Hensley ML, O’Reilly EM, et al. Gemcitabine-induced peripheral edema: report on 15 cases and review of the literature. Am J Clin Oncol. 2003;26(3):247–51.

    CAS  PubMed  Google Scholar 

  110. Geffen DB, Horowitz J. Gemcitabine-induced severe extremity edema with muscle contractures and subsequent prevention with prednisone. Isr Med Assoc J. 2000;2(7):552–3.

    CAS  PubMed  Google Scholar 

  111. Katsenos S, Nikolopoulou M. Gemcitabine-induced severe peripheral edema in a patient with lung cancer. J Pharm Pract. 2012;25(3):393–5.

    Article  PubMed  Google Scholar 

  112. Friedlander PA, Bansal R, Schwartz L, Wagman R, Posner J, Kemeny N. Gemcitabine-related radiation recall preferentially involves internal tissue and organs. Cancer. 2004;100(9):1793–9.

    Article  PubMed  Google Scholar 

  113. Jeter MD, Janne PA, Brooks S, Burstein HJ, Wen P, Fuchs CS, et al. Gemcitabine-induced radiation recall. Int J Radiat Oncol Biol Phys. 2002;53(2):394–400.

    Article  PubMed  Google Scholar 

  114. Eckardt MA, Bean A, Selch MT, Federman N. A child with gemcitabine-induced severe radiation recall myositis resulting in a compartment syndrome. J Pediatr Hematol Oncol. 2013;35(2):156–61.

    Article  PubMed  Google Scholar 

  115. del Pozo J, Martinez W, Yebra-Pimentel MT, Almagro M, Pena-Penabad C, Fonseca E. Linear immunoglobulin A bullous dermatosis induced by gemcitabine. Ann Pharmacother. 2001;35(7–8):891–3.

    Article  PubMed  Google Scholar 

  116. Ben Zvi M, Vaknine H, Menczer J, Peled O, Ben Shem E, Schreiber L, et al. Gemcitabine-induced subacute cutaneous lupus erythematosus: a case report. Chemotherapy. 2016;61(5):236–9.

    Article  PubMed  CAS  Google Scholar 

  117. Wiznia LE, Subtil A, Choi JN. Subacute cutaneous lupus erythematosus induced by chemotherapy: gemcitabine as a causative agent. JAMA Dermatol. 2013;149(9):1071–5.

    Article  PubMed  Google Scholar 

  118. Aznab M, Khazaei M. Stevens-Johnson syndrome patient received combination chemotherapy gemcitabine, cisplatin, and 5-FU for biliary tract cancer. Iran J Cancer Prev. 2016;9(3):e4211.

    PubMed  PubMed Central  Google Scholar 

  119. Mermershtain W, Cohen AD, Lazarev I, Grunwald M, Ariad S. Toxic epidermal necrolysis associated with gemcitabine therapy in a patient with metastatic transitional cell carcinoma of the bladder. J Chemother. 2003;15(5):510–1.

    CAS  PubMed  Google Scholar 

  120. Sommers KR, Kong KM, Bui DT, Fruehauf JP, Holcombe RF. Stevens-Johnson syndrome/toxic epidermal necrolysis in a patient receiving concurrent radiation and gemcitabine. Anticancer Drugs. 2003;14(8):659–62.

    Article  CAS  PubMed  Google Scholar 

  121. Agarwal KK, Nath AK, Thappa DM. Methotrexate toxicity presenting as ulceration of psoriatic plaques: a report of two cases. Indian J Dermatol Venereol Leprol. 2008;74(5):481–4.

    Article  PubMed  Google Scholar 

  122. Kaplan DL, Olsen EA. Erosion of psoriatic plaques after chronic methotrexate administration. Int J Dermatol. 1988;27(1):59–62.

    Article  CAS  PubMed  Google Scholar 

  123. Pearce HP, Wilson BB. Erosion of psoriatic plaques: an early sign of methotrexate toxicity. J Am Acad Dermatol. 1996;35(5 Pt 2):835–8.

    Article  CAS  PubMed  Google Scholar 

  124. Kazlow DW, Federgrun D, Kurtin S, Lebwohl MG. Cutaneous ulceration caused by methotrexate. J Am Acad Dermatol. 2003;49(2 Suppl Case Reports):S197–8.

    Google Scholar 

  125. Del Pozo J, Martinez W, Garcia-Silva J, Almagro M, Pena-Penabad C, Fonseca E. Cutaneous ulceration as a sign of methotrexate toxicity. Eur J Dermatol. 2001;11(5):450–2.

    PubMed  Google Scholar 

  126. Feizy V, Namazi MR, Barikbin B, Ehsani A. Methotrexate-induced acral erythema with bullous reaction. Dermatol Online J. 2003;9(1):14.

    PubMed  Google Scholar 

  127. Hellier I, Bessis D, Sotto A, Margueritte G, Guilhou JJ. High-dose methotrexate-induced bullous variant of acral erythema. Arch Dermatol. 1996;132(5):590–1.

    Article  CAS  PubMed  Google Scholar 

  128. Millot F, Auriol F, Brecheteau P, Guilhot F. Acral erythema in children receiving high-dose methotrexate. Pediatr Dermatol. 1999;16(5):398–400.

    Article  CAS  PubMed  Google Scholar 

  129. Morrell DS, Challgren E, Eapen M, Esterly NB. Bullous acral erythema secondary to high-dose methotrexate. J Pediatr Hematol Oncol. 2002;24(3):240.

    Article  PubMed  Google Scholar 

  130. Postovsky S, Ben Arush MW. Acral erythema caused by high-dose methotrexate therapy in patients with osteogenic sarcoma. Pediatr Hematol Oncol. 2005;22(2):167–73.

    Article  CAS  PubMed  Google Scholar 

  131. Tezer H, Kuskonmaz B, Kara A, Devrim I, Tuncer M, Cengiz AB, et al. Intravenous immunoglobulin in the treatment of severe methotrexate-induced acral erythema. J Pediatr Hematol Oncol. 2008;30(5):391–3.

    Article  PubMed  Google Scholar 

  132. Varela CR, McNamara J, Antaya RJ. Acral erythema with oral methotrexate in a child. Pediatr Dermatol. 2007;24(5):541–6.

    Article  PubMed  Google Scholar 

  133. Werchniak AE, Chaffee S, Dinulos JG. Methotrexate-induced bullous acral erythema in a child. J Am Acad Dermatol. 2005;52(5 Suppl 1):S93–5.

    Article  PubMed  Google Scholar 

  134. Zils K, Wilhelm M, Reeh T, Bielack S. Bullous variant of acral erythema in a child after high-dose methotrexate. Pediatr Hematol Oncol. 2012;29(4):378–9.

    Article  PubMed  Google Scholar 

  135. Ranawaka RR. Patterns of chromonychia during chemotherapy in patients with skin type V and outcome after 1 year of follow-up. Clin Exp Dermatol. 2009;34(8):e920–6.

    Article  CAS  PubMed  Google Scholar 

  136. Susser WS, Whitaker-Worth DL, Grant-Kels JM. Mucocutaneous reactions to chemotherapy. J Am Acad Dermatol. 1999;40(3):367–98; quiz 99–400.

    Article  CAS  PubMed  Google Scholar 

  137. Chittari K, Tagboto S, Tan BB. Cyclophosphamide-induced nail discoloration and skin hyperpigmentation: a rare presentation. Clin Exp Dermatol. 2009;34(3):405–6.

    Article  CAS  PubMed  Google Scholar 

  138. Singal R, Tunnessen WW Jr, Wiley JM, Hood AF. Discrete pigmentation after chemotherapy. Pediatr Dermatol. 1991;8(3):231–5.

    Article  CAS  PubMed  Google Scholar 

  139. Youssef M, Mokni S, Belhadjali H, Aouem K, Moussa A, Laatiri A, et al. Cyclophosphamide-induced generalised reticulated skin pigmentation: a rare presentation. Int J Clin Pharmacol. 2013;35(3):309–12.

    Article  Google Scholar 

  140. Koppel RA, Boh EE. Cutaneous reactions to chemotherapeutic agents. Am J Med Sci. 2001;321(5):327–35.

    Article  CAS  PubMed  Google Scholar 

  141. Webber KA, Kos L, Holland KE, Margolis DA, Drolet BA. Intertriginous eruption associated with chemotherapy in pediatric patients. Arch Dermatol. 2007;143(1):67–71.

    Article  PubMed  Google Scholar 

  142. Alley E, Green R, Schuchter L. Cutaneous toxicities of cancer therapy. Curr Opin Oncol. 2002;14(2):212–6.

    Article  CAS  PubMed  Google Scholar 

  143. Teresi ME, Murry DJ, Cornelius AS. Ifosfamide-induced hyperpigmentation. Cancer. 1993;71(9):2873–5.

    Article  CAS  PubMed  Google Scholar 

  144. Burgin S. New drugs, new rashes: update on cutaneous drug reactions. Adv Dermatol. 2005;21:279–302.

    Article  PubMed  Google Scholar 

  145. Prussick R, Horn TD, Wilson WH, Turner MC. A characteristic eruption associated with ifosfamide, carboplatin, and etoposide chemotherapy after pretreatment with recombinant interleukin-1 alpha. J Am Acad Dermatol. 1996;35(5 Pt 1):705–9.

    Article  CAS  PubMed  Google Scholar 

  146. Greenspan EM, Jaffrey I, Bruckner H. Thiotepa, cutaneous reactions, and efficacy. JAMA. 1977;237(21):2288.

    Article  CAS  PubMed  Google Scholar 

  147. Finlay JL, Goldman S, Wong MC, Cairo M, Garvin J, August C, et al. Pilot study of high-dose thiotepa and etoposide with autologous bone marrow rescue in children and young adults with recurrent CNS tumors. The Children’s Cancer Group. J Clin Oncol. 1996;14(9):2495–503.

    Article  CAS  PubMed  Google Scholar 

  148. Horn TD, Beveridge RA, Egorin MJ, Abeloff MD, Hood AF. Observations and proposed mechanism of N,N′,N″-triethylenethiophosphoramide (thiotepa)-induced hyperpigmentation. Arch Dermatol. 1989;125(4):524–7.

    Article  CAS  PubMed  Google Scholar 

  149. Lucidarme N, Valteau-Couanet D, Oberlin O, Couanet D, Kalifa C, Beaujean F, et al. Phase II study of high-dose thiotepa and hematopoietic stem cell transplantation in children with solid tumors. Bone Marrow Transplant. 1998;22(6):535–40.

    Article  CAS  PubMed  Google Scholar 

  150. Saarinen UM, Hovi L, Makipernaa A, Riikonen P. High-dose thiotepa with autologous bone marrow rescue in pediatric solid tumors. Bone Marrow Transplant. 1991;8(5):369–76.

    CAS  PubMed  Google Scholar 

  151. Przepiorka D, Dimopoulos M, Smith T, Ippoliti C, Diener K, Luna M, et al. Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for marrow transplantation: risk factors for early regimen-related toxicity. Ann Hematol. 1994;68(4):183–8.

    Article  CAS  PubMed  Google Scholar 

  152. Wolff SN, Herzig RH, Fay JW, LeMaistre CF, Brown RA, Frei-Lahr D, et al. High-dose N,N′,N″-triethylenethiophosphoramide (thiotepa) with autologous bone marrow transplantation: phase I studies. Semin Oncol. 1990;17(1 Suppl 3):2–6.

    CAS  PubMed  Google Scholar 

  153. Rosman IS, Lloyd BM, Hayashi RJ, Bayliss SJ. Cutaneous effects of thiotepa in pediatric patients receiving high-dose chemotherapy with autologous stem cell transplantation. J Am Acad Dermatol. 2008;58(4):575–8.

    Article  PubMed  Google Scholar 

  154. Kroon HM, Huismans AM, Kam PC, Thompson JF. Isolated limb infusion with melphalan and actinomycin D for melanoma: a systematic review. J Surg Oncol. 2014;109(4):348–51.

    Article  CAS  PubMed  Google Scholar 

  155. Malacarne P, Zavagli G. Melphalan-induced melanonychia striata. Arch Dermatol Res. 1977;258(1):81–3.

    Article  CAS  PubMed  Google Scholar 

  156. Adam BA, Ismail R, Sivanesan S. Busulfan hyperpigmentation: light and electron microscopic studies. J Dermatol. 1980;7(6):405–11.

    Article  CAS  PubMed  Google Scholar 

  157. Bandini G, Belardinelli A, Rosti G, Calori E, Motta MR, Rizzi S, et al. Toxicity of high-dose busulphan and cyclophosphamide as conditioning therapy for allogeneic bone marrow transplantation in adults with haematological malignancies. Bone Marrow Transplant. 1994;13(5):577–81.

    CAS  PubMed  Google Scholar 

  158. Feingold ML, Koss LG. Effects of long-term administration of busulfan. Report of a patient with generalized nuclear abnormalities, carcinoma of vulva, and pulmonary fibrosis. Arch Intern Med. 1969;124(1):66–71.

    Article  CAS  PubMed  Google Scholar 

  159. Haut A, Abbott WS, Wintrobe MM, Cartwright GE. Busulfan in the treatment of chronic myelocytic leukemia. The effect of long term intermittent therapy. Blood. 1961;17:1–19.

    CAS  PubMed  Google Scholar 

  160. Simonart T, Decaux G, Gourdin JM, Peny MO, Noel JC, Leclercq-Smekens M, et al. Hyperpigmentation induite par le busulfan: une observation avec etude ultrastructurale [Hyperpigmentation induced by busulfan: a case with ultrastructure examination]. Ann Dermatol Venereol. 1999;126(5):439–40 (in French).

    Google Scholar 

  161. Harrold BP. Syndrome resembling Addison’s disease following prolonged treatment with busulphan. Br Med J. 1966;1(5485):463–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  162. Burns WA, McFarland W, Matthews MJ. Toxic manifestations of busulfan therapy. Med Ann Dist Columbia. 1971;40(9):567–72.

    CAS  PubMed  Google Scholar 

  163. Das S, Kourosh AS. Pigment changes and drug reactions. In: Hall JC, Hall BJ, editors. Cutaneous drug eruptions: diagnosis, histopathology and therapy. London: Springer; 2015. p. 95.

    Google Scholar 

  164. Yarbro JW. Mechanism of action of hydroxyurea. Semin Oncol. 1992;19(3 Suppl 9):1–10.

    CAS  PubMed  Google Scholar 

  165. Kennedy BJ, Smith LR, Goltz RW. Skin changes secondary to hydroxyurea therapy. Arch Dermatol. 1975;111(2):183–7.

    Article  CAS  PubMed  Google Scholar 

  166. Burns DA, Sarkany I, Gaylarde P. Effects of hydroxyurea therapy on normal skin: a case report. Clin Exp Dermatol. 1980;5(4):447–9.

    Article  CAS  PubMed  Google Scholar 

  167. Gropper CA, Don PC, Sadjadi MM. Nail and skin hyperpigmentation associated with hydroxyurea therapy for polycythemia vera. Int J Dermatol. 1993;32(10):731–3.

    Article  CAS  PubMed  Google Scholar 

  168. Kelsey PR. Multiple longitudinal pigmented nail bands during hydroxyurea therapy. Clin Lab Haematol. 1992;14(4):337–8.

    Article  CAS  PubMed  Google Scholar 

  169. Vomvouras S, Pakula AS, Shaw JM. Multiple pigmented nail bands during hydroxyurea therapy: an uncommon finding. J Am Acad Dermatol. 1991;24(6 Pt 1):1016–7.

    Article  CAS  PubMed  Google Scholar 

  170. O’Branski EE, Ware RE, Prose NS, Kinney TR. Skin and nail changes in children with sickle cell anemia receiving hydroxyurea therapy. J Am Acad Dermatol. 2001;44(5):859–61.

    Article  PubMed  Google Scholar 

  171. Daoud MS, Gibson LE, Pittelkow MR. Hydroxyurea dermopathy: a unique lichenoid eruption complicating long-term therapy with hydroxyurea. J Am Acad Dermatol. 1997;36(2 Pt 1):178–82.

    Article  CAS  PubMed  Google Scholar 

  172. Layton AM, Cotterill JA. Immunological changes in hydroxyurea-induced collagen disease. Br J Dermatol. 1994;131(4):581–2.

    Article  CAS  PubMed  Google Scholar 

  173. Yanes DA, Mosser-Goldfarb JL. A cutaneous lupus erythematosus-like eruption induced by hydroxyurea. Pediatr Dermatol. 2017;34(1):e30–1. Epub 2016 Nov 4

    Article  PubMed  Google Scholar 

  174. Layton AM, Cotterill JA, Tomlinson IW. Hydroxyurea-induced lupus erythematosus. Br J Dermatol. 1994;130(5):687–8.

    Article  CAS  PubMed  Google Scholar 

  175. Ito E, Muro Y, Shibata A, Sugiura K, Akiyama M. Hydroxyurea-induced amyopathic dermatomyositis presenting with heliotrope erythema. Dermatol Online J. 2014;20(8).

    Google Scholar 

  176. de Unamuno-Bustos B, Ballester-Sanchez R, Sabater Marco V, Vilata-Corell JJ. Dermatomyositis-like eruption associated with hydroxyurea therapy: a premalignant condition? Actas Dermosifiliogr. 2014;105(9):876–8.

    Article  PubMed  Google Scholar 

  177. Nofal A, El-Din ES. Hydroxyurea-induced dermatomyositis: true amyopathic dermatomyositis or dermatomyositis-like eruption? Int J Dermatol. 2012;51(5):535–41.

    Article  PubMed  Google Scholar 

  178. Janerowicz D, Czarnecka-Operacz M, Stawny M, Silny W. Dermatomyositis-like eruption induced by hydroxyurea: a case report. Acta Dermatovenerol Alp Pannonica Adriat. 2009;18(3):131–4.

    PubMed  Google Scholar 

  179. Elliott R, Davies M, Harmse D. Dermatomyositis-like eruption with long-term hydroxyurea. J Dermatolog Treat. 2006;17(1):59–60.

    Article  CAS  PubMed  Google Scholar 

  180. Dacey MJ, Callen JP. Hydroxyurea-induced dermatomyositis-like eruption. J Am Acad Dermatol. 2003;48(3):439–41.

    Article  PubMed  Google Scholar 

  181. Marie I, Joly P, Levesque H, Heron F, Courville P, Cailleux N, et al. Pseudo-dermatomyositis as a complication of hydroxyurea therapy. Clin Exp Rheumatol. 2000;18(4):536–7.

    CAS  PubMed  Google Scholar 

  182. Bahadoran P, Castanet J, Lacour JP, Perrin C, Del Giudice P, Mannocci N, et al. Pseudo-dermatomyositis induced by long-term hydroxyurea therapy: report of two cases. Br J Dermatol. 1996;134(6):1161–3.

    Article  CAS  PubMed  Google Scholar 

  183. Senet P, Aractingi S, Porneuf M, Perrin P, Duterque M. Hydroxyurea-induced dermatomyositis-like eruption. Br J Dermatol. 1995;133(3):455–9.

    Article  CAS  PubMed  Google Scholar 

  184. Richard M, Truchetet F, Friedel J, Leclech C, Heid E. Skin lesions simulating chronic dermatomyositis during long-term hydroxyurea therapy. J Am Acad Dermatol. 1989;21(4 Pt 1):797–9.

    Article  CAS  PubMed  Google Scholar 

  185. Seidler AM, Gottlieb AB. Dermatomyositis induced by drug therapy: a review of case reports. J Am Acad Dermatol. 2008;59(5):872–80.

    Article  PubMed  Google Scholar 

  186. Bader U, Banyai M, Boni R, Burg G, Hafner J. Leg ulcers in patients with myeloproliferative disorders: disease- or treatment-related? Dermatology. 2000;200(1):45–8.

    Article  CAS  PubMed  Google Scholar 

  187. Antonioli E, Guglielmelli P, Pieri L, Finazzi M, Rumi E, Martinelli V, et al. Hydroxyurea-related toxicity in 3411 patients with Ph’-negative MPN. Am J Hematol. 2012;87(5):552–4.

    Article  PubMed  Google Scholar 

  188. Kikuchi K, Arita K, Tateishi Y, Onozawa M, Akiyama M, Shimizu H. Recurrence of hydroxyurea-induced leg ulcer after discontinuation of treatment. Acta Derm Venereol. 2011;91(3):373–4.

    Article  CAS  PubMed  Google Scholar 

  189. Best PJ, Daoud MS, Pittelkow MR, Petitt RM. Hydroxyurea-induced leg ulceration in 14 patients. Ann Intern Med. 1998;128(1):29–32.

    Article  CAS  PubMed  Google Scholar 

  190. Quattrone F, Dini V, Barbanera S, Zerbinati N, Romanelli M. Cutaneous ulcers associated with hydroxyurea therapy. J Tissue Viability. 2013;22(4):112–21.

    Article  PubMed  Google Scholar 

  191. Turner ML. Sun, drugs, and skin cancer: a continuing saga. Arch Dermatol. 2010;146(3):329–31.

    Article  PubMed  Google Scholar 

  192. Genc DB, Canpolat C, Berrak SG. Clinical features and management of carboplatin-related hypersensitivity reactions in pediatric low-grade glioma. Support Care Cancer. 2012;20(2):385–93.

    Article  PubMed  Google Scholar 

  193. Lafay-Cousin L, Sung L, Carret AS, Hukin J, Wilson B, Johnston DL, et al. Carboplatin hypersensitivity reaction in pediatric patients with low-grade glioma: a Canadian Pediatric Brain Tumor Consortium experience. Cancer. 2008;112(4):892–9.

    Article  CAS  PubMed  Google Scholar 

  194. Shah AC, Minturn JE, Li Y, Belasco JB, Phillips PC, Kang TI, et al. Carboplatin rechallenge after hypersensitivity reactions in pediatric patients with low-grade glioma. Pediatr Blood Cancer. 2016;63(1):21–6.

    Article  CAS  PubMed  Google Scholar 

  195. Dodgshun AJ, Hansford JR, Cole T, Choo S, Sullivan MJ. Carboplatin hypersensitivity reactions in pediatric low grade glioma are protocol specific and desensitization shows poor efficacy. Pediatr Blood Cancer. 2016;63(1):17–20.

    Article  CAS  PubMed  Google Scholar 

  196. Genc DB, Berrak SG, Canpolat C. Comment on: Carboplatin hypersensitivity reactions in pediatric low-grade glioma are protocol specific and desensitization shows poor efficacy. Pediatr Blood Cancer. 2016;63(1):174.

    Article  PubMed  Google Scholar 

  197. Yanagi T, Akiyama M, Aoyagi S, Shibaki A, Homma A, Shimizu H. Marked and restricted cutaneous pigmentation induced by selective intra-arterial cisplatin infusion. J Am Acad Dermatol. 2006;54(2):362–3.

    Article  PubMed  Google Scholar 

  198. Jaffe N. Pediatric osteosarcoma: treatment of the primary tumor with intraarterial cis-diamminedichloroplatinum-II (CDP)—advantages, disadvantages, and controversial issues. Cancer Treat Res. 1993;62:75–84.

    Article  CAS  PubMed  Google Scholar 

  199. Al-Lamki Z, Pearson P, Jaffe N. Localized cisplatin hyperpigmentation induced by pressure. A case report. Cancer. 1996;77(8):1578–81.

    Article  CAS  PubMed  Google Scholar 

  200. Kim KJ, Chang SE, Choi JH, Sung KJ, Moon KC, Koh JK. Periungal hyperpigmentation induced by cisplatin. Clin Exp Dermatol. 2002;27(2):118–9.

    Article  CAS  PubMed  Google Scholar 

  201. Hortobagyi GN, Buzdar AU, Marcus CE, Smith TL. Immediate and long-term toxicity of adjuvant chemotherapy regimens containing doxorubicin in trials at M.D. Anderson Hospital and Tumor Institute. NCI Monogr. 1986;(1):105–9.

    Google Scholar 

  202. Samuels BL, Vogelzang NJ, Ruane M, Simon MA. Continuous venous infusion of doxorubicin in advanced sarcomas. Cancer Treat Rep. 1987;71(10):971–2.

    CAS  PubMed  Google Scholar 

  203. Schrijvers DL. Extravasation: a dreaded complication of chemotherapy. Ann Oncol. 2003;14(Suppl 3):iii26–30.

    Google Scholar 

  204. Marina NM, Cochrane D, Harney E, Zomorodi K, Blaney S, Winick N, et al. Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: a pediatric oncology group study. Clin Cancer Res. 2002;8(2):413–8.

    CAS  PubMed  Google Scholar 

  205. von Moos R, Thuerlimann BJ, Aapro M, Rayson D, Harrold K, Sehouli J, et al. Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts. Eur J Cancer. 2008;44(6):781–90.

    Article  CAS  Google Scholar 

  206. Tanyi JL, Smith JA, Ramos L, Parker CL, Munsell MF, Wolf JK. Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer. Gynecol Oncol. 2009;114(2):219–24.

    Article  CAS  PubMed  Google Scholar 

  207. Coleman RE, Biganzoli L, Canney P, Dirix L, Mauriac L, Chollet P, et al. A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993). Eur J Cancer. 2006;42(7):882–7.

    Article  CAS  PubMed  Google Scholar 

  208. Al-Batran SE, Meerpohl HG, von Minckwitz G, Atmaca A, Kleeberg U, Harbeck N, et al. Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40 mg/m2 every 4 weeks in previously treated patients with metastatic breast cancer. Oncology. 2006;70(2):141–6.

    Google Scholar 

  209. Ranson MR, Carmichael J, O’Byrne K, Stewart S, Smith D, Howell A. Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. J Clin Oncol. 1997;15(10):3185–91.

    Article  CAS  PubMed  Google Scholar 

  210. Lotem M, Hubert A, Lyass O, Goldenhersh MA, Ingber A, Peretz T, et al. Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin. Arch Dermatol. 2000;136(12):1475–80.

    Article  CAS  PubMed  Google Scholar 

  211. Sanchez Henarejos P, Ros Martinez S, Marin Zafra GR, Alonso Romero JL, Navarrete MA. Intertrigo-like eruption caused by pegylated liposomal doxorubicin (PLD). Clin Transl Oncol. 2009;11(7):486–7.

    Article  PubMed  Google Scholar 

  212. Korver GE, Ronald H, Petersen MJ. An intertrigo-like eruption from pegylated liposomal doxorubicin. J Drugs Dermatol. 2006;5(9):901–2.

    PubMed  Google Scholar 

  213. Coppes MJ, Jorgenson K, Arlette JP. Cutaneous toxicity following the administration of dactinomycin. Med Pediatr Oncol. 1997;29(3):226–7.

    Article  CAS  PubMed  Google Scholar 

  214. Kanwar VS, Gajjar A, Ribeiro RC, Bowman L, Parham DM, Jenkins JJ 3rd. Unusual cutaneous toxicity following treatment with dactinomycin: a report of two cases. Med Pediatr Oncol. 1995;24(5):329–33.

    Article  CAS  PubMed  Google Scholar 

  215. Ridola V, Mahe E, Fawaz O, Galmiche L, Patte C, Grill J. Dactinomycin-induced, severe lichenoid eruption in a child. Pediatr Dermatol. 2006;23(5):503–6.

    Article  CAS  PubMed  Google Scholar 

  216. Van Gool SW, van den Oord J, Uyttebroeck A, Brock P. Cutaneous toxicity following administration of dactinomycin. Med Pediatr Oncol. 1998;31(2):128.

    Article  PubMed  Google Scholar 

  217. Blatt J, Lee PA. Severe acne and hyperandrogenemia following dactinomycin. Med Pediatr Oncol. 1993;21(5):373–4.

    Google Scholar 

  218. Tan CT, Dargeon HW, Burchenal JH. The effect of actinomycin D on cancer in childhood. Pediatrics. 1959;24:544–61.

    CAS  PubMed  Google Scholar 

  219. Stein RS. Radiation-recall enteritis after actinomycin-D and adriamycin therapy. South Med J. 1978;71(8):960–1.

    Article  CAS  PubMed  Google Scholar 

  220. Burris HA 3rd, Hurtig J. Radiation recall with anticancer agents. Oncologist. 2010;15(11):1227–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  221. Prindaville B, Horii KA, Canty KM. Radiation Recall Dermatitis Secondary to Dactinomycin. Pediatr Dermatol. 2016;33(5):e278–9. Epub 2016 Jul 5.

    Article  PubMed  Google Scholar 

  222. Moulin G, Fiere B, Beyvin A. Pigmentation cutanee par la bleomycine [Cutaneous pigmentation caused by bleomycin]. Bull Soc Fr Dermatol Syphiligr. 1970;77(2):293–6.

    Google Scholar 

  223. Yagoda A, Mukherji B, Young C, Etcubanas E, Lamonte C, Smith JR, et al. Bleomycin, an antitumor antibiotic. Clinical experience in 274 patients. Ann Intern Med. 1972;77(6):861–70.

    Article  CAS  PubMed  Google Scholar 

  224. Cortina P, Garrido JA, Tomas JF, Unamuno P, Armijo M. ‘Flagellate’ erythema from bleomycin. With histopathological findings suggestive of inflammatory oncotaxis. Dermatologica. 1990;180(2):106–9.

    Article  CAS  PubMed  Google Scholar 

  225. Duhra P, Ilchyshyn A, Das RN. Bleomycin-induced flagellate erythema. Clin Exp Dermatol. 1991;16(3):216–7.

    Article  CAS  PubMed  Google Scholar 

  226. Mowad CM, Nguyen TV, Elenitsas R, Leyden JJ. Bleomycin-induced flagellate dermatitis: a clinical and histopathological review. Br J Dermatol. 1994;131(5):700–2.

    Article  CAS  PubMed  Google Scholar 

  227. Vignini M, Miori L, Brusamolino E, Pelfini C. Linear streaking after bleomycin administration. Clin Exp Dermatol. 1989;14(3):261.

    Article  CAS  PubMed  Google Scholar 

  228. Brazzelli V, Barruscotti S, Calafiore L, Zecca M, Borroni G. Bleomycin-induced flagellate dermatitis: report of four paediatric cases. J Eur Acad Dermatol Venereol. 2014;28(5):670–1.

    Article  CAS  PubMed  Google Scholar 

  229. Fernandez-Obregon AC, Hogan KP, Bibro MK. Flagellate pigmentation from intrapleural bleomycin. A light microscopy and electron microscopy study. J Am Acad Dermatol. 1985;13(3):464–8.

    Article  CAS  PubMed  Google Scholar 

  230. Polla BS, Merot Y, Saurat JH, Slosman D. Flagellate pigmentation from bleomycin. J Am Acad Dermatol. 1986;14(4):690.

    Article  CAS  PubMed  Google Scholar 

  231. vonHilsheimer GE, Norton SA. Delayed bleomycin-induced hyperpigmentation and pressure on the skin. J Am Acad Dermatol. 2002;46(4):642–3.

    Article  PubMed  Google Scholar 

  232. Zaki I, Haslam P, Scerri L. Flagellate erythema after intraperitoneal bleomycin. Clin Exp Dermatol. 1994;19(4):366.

    Article  CAS  PubMed  Google Scholar 

  233. Abess A, Keel DM, Graham BS. Flagellate hyperpigmentation following intralesional bleomycin treatment of verruca plantaris. Arch Dermatol. 2003;139(3):337–9.

    Article  PubMed  Google Scholar 

  234. Hansen SW, Olsen N. Raynaud’s phenomenon in patients treated with cisplatin, vinblastine , and bleomycin for germ cell cancer: measurement of vasoconstrictor response to cold. J Clin Oncol. 1989;7(7):940–2.

    Google Scholar 

  235. Berger CC, Bokemeyer C, Schneider M, Kuczyk MA, Schmoll HJ. Secondary Raynaud’s phenomenon and other late vascular complications following chemotherapy for testicular cancer. Eur J Cancer. 1995;31A(13–14):2229–38.

    Google Scholar 

  236. Vanhooteghem O, Richert B, de la Brassinne M. Raynaud phenomenon after treatment of verruca vulgaris of the sole with intralesional injection of bleomycin. Pediatr Dermatol. 2001;18(3):249–51.

    Article  CAS  PubMed  Google Scholar 

  237. Correia O, Ribas F, Azevedo R, Rodrigues H, Delgado L. Gangrene of the fingertips after bleomycin and methotrexate. Cutis. 2000;66.(4(4):271–2.

    CAS  PubMed  Google Scholar 

  238. Surville-Barland J, Caumes E, Ankri A, Frances C, Katlama C, Chosidow O. Bleomycin-induced digital gangrene. Eur J Dermatol. 1998;8(3):221.

    CAS  PubMed  Google Scholar 

  239. Elomaa I, Pajunen M, Virkkunen P. Raynaud’s phenomenon progressing to gangrene after vincristine and bleomycin therapy. Acta Med Scand. 1984;216(3):323–6.

    Google Scholar 

  240. Inaoki M, Kawabata C, Nishijima C, Yoshio N, Kita T. Case of bleomycin-induced scleroderma. J Dermatol. 2012;39(5):482–4.

    Article  PubMed  Google Scholar 

  241. Sharma SK, Handa R, Sood R, Aggarwal P, Biswas A, Kumar U, et al. Bleomycin-induced scleroderma. J Assoc Physicians India. 2004;52:76–7.

    PubMed  Google Scholar 

  242. Kumar R, Pai V. Bleomycin induced flagellate pigmentation. Indian Pediatr. 2006;43(1):74–5.

    PubMed  Google Scholar 

  243. Yamamoto T. Bleomycin and the skin. Br J Dermatol. 2006;155(5):869–75.

    Article  CAS  PubMed  Google Scholar 

  244. Kadota RP, Stewart CF, Horn M, Kuttesch JF Jr, Burger PC, Kepner JL, et al. Topotecan for the treatment of recurrent or progressive central nervous system tumors - a pediatric oncology group phase II study. J Neurooncol. 1999;43(1):43–7.

    Article  CAS  PubMed  Google Scholar 

  245. Nitschke R, Parkhurst J, Sullivan J, Harris MB, Bernstein M, Pratt C. Topotecan in pediatric patients with recurrent and progressive solid tumors: a Pediatric Oncology Group phase II study. J Pediatr Hematol Oncol. 1998;20(4):315–8.

    Article  CAS  PubMed  Google Scholar 

  246. Furman WL, Stewart CF, Kirstein M, Kepner JL, Bernstein ML, Kung F, et al. Protracted intermittent schedule of topotecan in children with refractory acute leukemia: a pediatric oncology group study. J Clin Oncol. 2002;20(6):1617–24.

    Article  CAS  PubMed  Google Scholar 

  247. Blaney SM, Needle MN, Gillespie A, Sato JK, Reaman GH, Berg SL, et al. Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children’s Cancer Group Study. Clin Cancer Res. 1998;4(2):357–60.

    CAS  PubMed  Google Scholar 

  248. Kushner BH, Kramer K, Meyers PA, Wollner N, Cheung NK. Pilot study of topotecan and high-dose cyclophosphamide for resistant pediatric solid tumors. Med Pediatr Oncol. 2000;35(5):468–74.

    Article  CAS  PubMed  Google Scholar 

  249. Pratt CB, Stewart C, Santana VM, Bowman L, Furman W, Ochs J, et al. Phase I study of topotecan for pediatric patients with malignant solid tumors. J Clin Oncol. 1994;12(3):539–43.

    Article  CAS  PubMed  Google Scholar 

  250. Minturn JE, Janss AJ, Fisher PG, Allen JC, Patti R, Phillips PC, et al. A phase II study of metronomic oral topotecan for recurrent childhood brain tumors. Pediatr Blood Cancer. 2011;56(1):39–44.

    Article  PubMed  Google Scholar 

  251. Stewart CF, Iacono LC, Chintagumpala M, Kellie SJ, Ashley D, Zamboni WC, et al. Results of a phase II upfront window of pharmacokinetically guided topotecan in high-risk medulloblastoma and supratentorial primitive neuroectodermal tumor. J Clin Oncol. 2004;22(16):3357–65.

    Article  CAS  PubMed  Google Scholar 

  252. Tubergen DG, Stewart CF, Pratt CB, Zamboni WC, Winick N, Santana VM, et al. Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a pediatric oncology group study. J Pediatr Hematol Oncol. 1996;18(4):352–61.

    Article  CAS  PubMed  Google Scholar 

  253. Wagner S, Erdlenbruch B, Langler A, Gnekow A, Kuhl J, Albani M, et al. Oral topotecan in children with recurrent or progressive high-grade glioma: a Phase I/II study by the German Society for Pediatric Oncology and Hematology. Cancer. 2004;100(8):1750–7.

    Article  CAS  PubMed  Google Scholar 

  254. Blaney SM, Phillips PC, Packer RJ, Heideman RL, Berg SL, Adamson PC, et al. Phase II evaluation of topotecan for pediatric central nervous system tumors. Cancer. 1996;78(3):527–31.

    Article  CAS  PubMed  Google Scholar 

  255. Astudillo PP, Durairaj P, Chan HS, Heon E, Gallie BL. Hypersensitivity to sub-Tenon’s topotecan in fibrin adhesive in patients with retinoblastoma. J AAPOS. 2015;19(1):86–7.

    Article  PubMed  Google Scholar 

  256. Bomgaars L, Kerr J, Berg S, Kuttesch J, Klenke R, Blaney SM. A phase I study of irinotecan administered on a weekly schedule in pediatric patients. Pediatr Blood Cancer. 2006;46(1):50–5.

    Article  CAS  PubMed  Google Scholar 

  257. Furman WL, Navid F, Daw NC, McCarville MB, McGregor LM, Spunt SL, et al. Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors. J Clin Oncol. 2009;27(27):4599–604.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  258. Vassal G, Doz F, Frappaz D, Imadalou K, Sicard E, Santos A, et al. A phase I study of irinotecan as a 3-week schedule in children with refractory or recurrent solid tumors. J Clin Oncol. 2003;21(20):3844–52.

    Article  CAS  PubMed  Google Scholar 

  259. Mugishima H, Matsunaga T, Yagi K, Asami K, Mimaya J, Suita S, et al. Phase I study of irinotecan in pediatric patients with malignant solid tumors. J Pediatr Hematol Oncol. 2002;24(2):94–100.

    Article  PubMed  Google Scholar 

  260. Whitlock JA, Greer JP, Lukens JN. Epipodophyllotoxin-related leukemia. Identification of a new subset of secondary leukemia. Cancer. 1991;68(3):600–4.

    Article  CAS  PubMed  Google Scholar 

  261. Smith MA, Rubinstein L, Ungerleider RS. Therapy-related acute myeloid leukemia following treatment with epipodophyllotoxins: estimating the risks. Med Pediatr Oncol. 1994;23(2):86–98.

    Article  CAS  PubMed  Google Scholar 

  262. Ezoe S. Secondary leukemia associated with the anti-cancer agent, etoposide, a topoisomerase II inhibitor. Int J Environ Res Public Health. 2012;9(7):2444–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  263. Kellie SJ, Crist WM, Pui CH, Crone ME, Fairclough DL, Rodman JH, et al. Hypersensitivity reactions to epipodophyllotoxins in children with acute lymphoblastic leukemia. Cancer. 1991;67(4):1070–5.

    Article  CAS  PubMed  Google Scholar 

  264. Kung F, Hayes FA, Krischer J, Mahoney D Jr, Leventhal B, Brodeur G, et al. Clinical trial of etoposide (VP-16) in children with recurrent malignant solid tumors. A phase II study from the Pediatric Oncology Group. Invest New Drugs. 1988;6(1):31–6.

    Article  CAS  PubMed  Google Scholar 

  265. Leguay Z, Bourneau-Martin D, Pellier I, Le Louet H, Drablier G, Lagarce L, et al. Successful treatment with etoposide base after an acute hypersensitivity reaction to etoposide phosphate. Pediatr Blood Cancer. 2016;63(3):571.

    Article  PubMed  Google Scholar 

  266. Ceci A, de Terlizzi M, Colella R, Balducci D, Toma MG, Zurlo MG, et al. Etoposide in recurrent childhood Langerhans’ cell histiocytosis: an Italian cooperative study. Cancer. 1988;62(12):2528–31.

    Article  CAS  PubMed  Google Scholar 

  267. Kushner BH, Kramer K, Cheung NK. Oral etoposide for refractory and relapsed neuroblastoma. J Clin Oncol. 1999;17(10):3221–5.

    Article  CAS  PubMed  Google Scholar 

  268. Steuber CP, Holbrook T, Camitta B, Land VJ, Sexauer C, Krischer J. Toxicity trials of amsacrine (AMSA) and etoposide +/− azacitidine (AZ) in childhood acute non-lymphocytic leukemia (ANLL): a pilot study. Invest New Drugs. 1991;9(2):181–4.

    Article  CAS  PubMed  Google Scholar 

  269. Mathew P, Ribeiro RC, Sonnichsen D, Relling M, Pratt C, Mahmoud H, et al. Phase I study of oral etoposide in children with refractory solid tumors. J Clin Oncol. 1994;12(7):1452–7.

    Article  CAS  PubMed  Google Scholar 

  270. Needle MN, Molloy PT, Geyer JR, Herman-Liu A, Belasco JB, Goldwein JW, et al. Phase II study of daily oral etoposide in children with recurrent brain tumors and other solid tumors. Med Pediatr Oncol. 1997;29(1):28–32.

    Article  CAS  PubMed  Google Scholar 

  271. Nolte H, Carstensen H, Hertz H. VM-26 (teniposide)-induced hypersensitivity and degranulation of basophils in children. Am J Pediatr Hematol Oncol. 1988;10(4):308–12.

    Article  CAS  PubMed  Google Scholar 

  272. O’Dwyer PJ, King SA, Fortner CL, Leyland-Jones B. Hypersensitivity reactions to teniposide (VM-26): an analysis. J Clin Oncol. 1986;4(8):1262–9.

    Article  PubMed  Google Scholar 

  273. Hayes FA, Abromowitch M, Green AA. Allergic reactions to teniposide in patients with neuroblastoma and lymphoid malignancies. Cancer Treat Rep. 1985;69(4):439–41.

    CAS  PubMed  Google Scholar 

  274. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc. 1971;93(9):2325–7.

    Article  CAS  PubMed  Google Scholar 

  275. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer. 2004;4(4):253–65.

    Article  CAS  PubMed  Google Scholar 

  276. Schiff PB, Horwitz SB. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci U S A. 1980;77(3):1561–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  277. Bhalla K, Ibrado AM, Tourkina E, Tang C, Mahoney ME, Huang Y. Taxol induces internucleosomal DNA fragmentation associated with programmed cell death in human myeloid leukemia cells. Leukemia. 1993;7(4):563–8.

    CAS  PubMed  Google Scholar 

  278. Wang TH, Wang HS, Soong YK. Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. Cancer. 2000;88(11):2619–28.

    Article  CAS  PubMed  Google Scholar 

  279. Bhalla KN. Microtubule-targeted anticancer agents and apoptosis. Oncogene. 2003;22(56):9075–86.

    Article  CAS  PubMed  Google Scholar 

  280. Blaney SM, Seibel NL, O’Brien M, Reaman GH, Berg SL, Adamson PC, et al. Phase I trial of docetaxel administered as a 1-hour infusion in children with refractory solid tumors: a collaborative pediatric branch, National Cancer Institute and Children’s Cancer Group trial. J Clin Oncol. 1997;15(4):1538–43.

    Article  CAS  PubMed  Google Scholar 

  281. Hurwitz CA, Relling MV, Weitman SD, Ravindranath Y, Vietti TJ, Strother DR, et al. Phase I trial of paclitaxel in children with refractory solid tumors: a Pediatric Oncology Group Study. J Clin Oncol. 1993;11(12):2324–9.

    Article  CAS  PubMed  Google Scholar 

  282. Zwerdling T, Krailo M, Monteleone P, Byrd R, Sato J, Dunaway R, et al. Phase II investigation of docetaxel in pediatric patients with recurrent solid tumors: a report from the Children’s Oncology Group. Cancer. 2006;106(8):1821–8.

    Article  CAS  PubMed  Google Scholar 

  283. Andre N, Meille C. Taxanes in paediatric oncology: and now? Cancer Treat Rev. 2006;32(2):65–73.

    Article  CAS  PubMed  Google Scholar 

  284. Mora J, Cruz CO, Parareda A, de Torres C. Treatment of relapsed/refractory pediatric sarcomas with gemcitabine and docetaxel. J Pediatr Hematol Oncol. 2009;31(10):723–9.

    Article  CAS  PubMed  Google Scholar 

  285. Lee JA, Paik EK, Seo J, Kim DH, Lim JS, Yoo JY, et al. Radiotherapy and gemcitabine-docetaxel chemotherapy in children and adolescents with unresectable recurrent or refractory osteosarcoma. Jpn J Clin Oncol. 2016;46(2):138–43.

    PubMed  Google Scholar 

  286. Reynolds CP, Kang MH, Maris JM, Kolb EA, Gorlick R, Wu J, et al. Initial testing (stage 1) of the anti-microtubule agents cabazitaxel and docetaxel, by the pediatric preclinical testing program. Pediatr Blood Cancer. 2015;62(11):1897–905.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  287. Seibel NL, Blaney SM, O’Brien M, Krailo M, Hutchinson R, Mosher RB, et al. Phase I trial of docetaxel with filgrastim support in pediatric patients with refractory solid tumors: a collaborative Pediatric Oncology Branch, National Cancer Institute and Children’s Cancer Group trial. Clin Cancer Res. 1999;5(4):733–7.

    CAS  PubMed  Google Scholar 

  288. Navid F, Willert JR, McCarville MB, Furman W, Watkins A, Roberts W, et al. Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma. Cancer. 2008;113(2):419–25.

    Article  CAS  PubMed  Google Scholar 

  289. Palmerini E, Jones RL, Marchesi E, Paioli A, Cesari M, Longhi A, et al. Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone. BMC Cancer. 2016;16:280.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  290. Song BS, Seo J, Kim DH, Lim JS, Yoo JY, Lee JA. Gemcitabine and docetaxel for the treatment of children and adolescents with recurrent or refractory osteosarcoma: Korea Cancer Center Hospital experience. Pediatr Blood Cancer. 2014;61(8):1376–81.

    Article  CAS  PubMed  Google Scholar 

  291. Hurwitz CA, Strauss LC, Kepner J, Kretschmar C, Harris MB, Friedman H, et al. Paclitaxel for the treatment of progressive or recurrent childhood brain tumors: a pediatric oncology phase II study. J Pediatr Hematol Oncol. 2001;23(5):277–81.

    Article  CAS  PubMed  Google Scholar 

  292. Kretschmar CS, Kletzel M, Murray K, Thorner P, Joshi V, Marcus R, et al. Response to paclitaxel, topotecan, and topotecan-cyclophosphamide in children with untreated disseminated neuroblastoma treated in an upfront phase II investigational window: a pediatric oncology group study. J Clin Oncol. 2004;22(20):4119–26.

    Article  CAS  PubMed  Google Scholar 

  293. Rapkin L, Qayed M, Brill P, Martin M, Clark D, George BA, et al. Gemcitabine and docetaxel (GEMDOX) for the treatment of relapsed and refractory pediatric sarcomas. Pediatr Blood Cancer. 2012;59(5):854–8.

    Article  PubMed  Google Scholar 

  294. Geller JI, Wall D, Perentesis J, Blaney SM, Bernstein M. Pediatric Oncology Group s. Phase I study of paclitaxel with standard dose ifosfamide in children with refractory solid tumors: a Pediatric Oncology Group study (POG 9376). Pediatr Blood Cancer. 2009;52(3):346–50.

    Article  PubMed  PubMed Central  Google Scholar 

  295. Horton TM, Ames MM, Reid JM, Krailo MD, Pendergrass T, Mosher R, et al. A Phase 1 and pharmacokinetic clinical trial of paclitaxel for the treatment of refractory leukemia in children: a Children’s Oncology Group study. Pediatr Blood Cancer. 2008;50(4):788–92.

    Article  PubMed  Google Scholar 

  296. Yoon JH, Kwon MM, Park HJ, Park SY, Lim KY, Joo J, et al. A study of docetaxel and irinotecan in children and young adults with recurrent or refractory Ewing sarcoma family of tumors. BMC Cancer. 2014;14:622.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  297. Hayashi RJ, Blaney S, Sullivan J, Weitman S, Vietti T, Bernstein ML, et al. Phase 1 study of Paclitaxel administered twice weekly to children with refractory solid tumors: a pediatric oncology group study. J Pediatr Hematol Oncol. 2003;25(7):539–42.

    Article  PubMed  Google Scholar 

  298. Gosiengfiao Y, Reichek J, Woodman J, Ben-Ami T, Walterhouse D. Gemcitabine with or without docetaxel and resection for recurrent osteosarcoma: the experience at Children’s Memorial Hospital. J Pediatr Hematol Oncol. 2012;34(2):e63–5.

    Article  CAS  PubMed  Google Scholar 

  299. Mora J, Cruz O, Parareda A, Sola T, de Torres C. Treatment of disseminated paraganglioma with gemcitabine and docetaxel. Pediatr Blood Cancer. 2009;53(4):663–5.

    Article  PubMed  Google Scholar 

  300. Surico G, Muggeo P, De Leonardis F, Rigillo N. New paclitaxel-cisplatin based chemotherapy regimen for advanced stage, recurrent, or refractory neuroblastoma-preliminary report. Med Pediatr Oncol. 2003;40(2):130–2.

    Article  PubMed  Google Scholar 

  301. Vainionpaa L, Kovala T, Tolonen U, Lanning M. Vincristine therapy for children with acute lymphoblastic leukemia impairs conduction in the entire peripheral nerve. Pediatr Neurol. 1995;13(4):314–8.

    Article  CAS  PubMed  Google Scholar 

  302. Bates D, Eastman A. Microtubule destabilising agents: far more than just antimitotic anticancer drugs. Br J Clin Pharmacol. 2017;83(2):255–68.

    Article  CAS  PubMed  Google Scholar 

  303. Renbarger JL, McCammack KC, Rouse CE, Hall SD. Effect of race on vincristine -associated neurotoxicity in pediatric acute lymphoblastic leukemia patients. Pediatr Blood Cancer. 2008;50(4):769–71.

    Google Scholar 

  304. Diouf B, Crews KR, Lew G, Pei D, Cheng C, Bao J, et al. Association of an inherited genetic variant with vincristine -related peripheral neuropathy in children with acute lymphoblastic leukemia. JAMA. 2015;313(8):815–23.

    Google Scholar 

  305. Egbelakin A, Ferguson MJ, MacGill EA, Lehmann AS, Topletz AR, Quinney SK, et al. Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2011;56(3):361–7.

    Google Scholar 

  306. Sims RP. The effect of race on the CYP3A-mediated metabolism of vincristine in pediatric patients with acute lymphoblastic leukemia. J Oncol Pharm Pract. 2016;22(1):76–81.

    Google Scholar 

  307. Ceci A, de Terlizzi M, Colella R, Loiacono G, Balducci D, Surico G, et al. Langerhans cell histiocytosis in childhood: results from the Italian Cooperative AIEOP-CNR-H.X ’83 study. Med Pediatr Oncol. 1993;21(4):259–64.

    Article  CAS  PubMed  Google Scholar 

  308. Glade RS, Vinson K, Becton D, Bhutta S, Buckmiller LM. Management of complicated hemangiomas with vincristine /vinblastine : Quantitative response to therapy using MRI. Int J Pediatr Otorhinolaryngol. 2010;74(11):1221–5.

    Google Scholar 

  309. Perez J, Pardo J, Gomez C. Vincristine—an effective treatment of corticoid-resistant life-threatening infantile hemangiomas. Acta Oncol. 2002;41(2):197–9.

    Article  PubMed  Google Scholar 

  310. Moore J, Lee M, Garzon M, Soffer S, Kim E, Saouaf R, et al. Effective therapy of a vascular tumor of infancy with vincristine . J Pediatr Surg. 2001;36(8):1273–6.

    Google Scholar 

  311. Taki M, Ohi C, Yamashita A, Kobayashi M, Kobayashi N, Yoda T, et al. Successful treatment with vincristine of an infant with intractable Kasabach-Merritt syndrome. Pediatr Int. 2006;48(1):82–4.

    Google Scholar 

  312. Herrero Hernandez A, Escobosa Sanchez O, Acha GT. Successful treatment with vincristine in PHACES syndrome. Clin Transl Oncol. 2007;9(4):262–3.

    Google Scholar 

  313. Abass K, Saad H, Kherala M, Abd-Elsayed AA. Successful treatment of kasabach-merritt syndrome with vincristine and surgery: a case report and review of literature. Cases J. 2008;1(1):9.

    Google Scholar 

  314. Fahrtash F, McCahon E, Arbuckle S. Successful treatment of kaposiform hemangioendothelioma and tufted angioma with vincristine . J Pediatr Hematol Oncol. 2010;32(6):506–10.

    Google Scholar 

  315. Wang Z, Li K, Yao W, Dong K, Xiao X, Zheng S. Steroid-resistant kaposiform hemangioendothelioma: a retrospective study of 37 patients treated with vincristine and long-term follow-up. Pediatr Blood Cancer. 2015;62(4):577–80.

    Google Scholar 

  316. Wasserman JD, Mahant S, Carcao M, Perlman K, Pope E. Vincristine for successful treatment of steroid-dependent infantile hemangiomas. Pediatrics. 2015;135(6):e1501–5.

    Article  PubMed  Google Scholar 

  317. Heyn RM, Beatty EC Jr, Hammond D, Louis J, Pierce M, Murphy ML, et al. Vincristine in the treatment of acute leukemia in children. Pediatrics. 1966;38(1):82–91.

    CAS  PubMed  Google Scholar 

  318. Rosenstock JG, Evans AE, Schut L. Response to vincristine of recurrent brain tumors in children. J Neurosurg. 1976;45(2):135–40.

    Google Scholar 

  319. Skapek SX, Hawk BJ, Hoffer FA, Dahl GV, Granowetter L, Gebhardt MC, et al. Combination chemotherapy using vinblastine and methotrexate for the treatment of progressive desmoid tumor in children. J Clin Oncol. 1998;16(9):3021–7.

    Google Scholar 

  320. Bouffet E, Jakacki R, Goldman S, Hargrave D, Hawkins C, Shroff M, et al. Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma. J Clin Oncol. 2012;30(12):1358–63.

    Google Scholar 

  321. Fresneau B, Petit A, Courcoux MF, Tabone MD, Auvrignon A, Landman-Parker J, et al. Vinblastine in the treatment of children and adolescents with refractory immune thrombocytopenia. Am J Hematol. 2011;86(9):785–7.

    Article  CAS  PubMed  Google Scholar 

  322. Lafay-Cousin L, Holm S, Qaddoumi I, Nicolin G, Bartels U, Tabori U, et al. Weekly vinblastine in pediatric low-grade glioma patients with carboplatin allergic reaction. Cancer. 2005;103(12):2636–42.

    Google Scholar 

  323. Sullivan MP, Nora AH, Kulapongs P, Lane DM, Windmiller J, Thurman WG. Evaluation of vincristine sulfate and cyclophosphamide chemotherapy for metastatic neuroblastoma. Pediatrics. 1969;44(5):685–94.

    Google Scholar 

  324. Casanova M, Ferrari A, Spreafico F, Terenziani M, Massimino M, Luksch R, et al. Vinorelbine in previously treated advanced childhood sarcomas: evidence of activity in rhabdomyosarcoma. Cancer. 2002;94(12):3263–8.

    Article  CAS  PubMed  Google Scholar 

  325. Johansen M, Kuttesch J, Bleyer WA, Krailo M, Ames M, Madden T. Phase I evaluation of oral and intravenous vinorelbine in pediatric cancer patients: a report from the Children’s Oncology Group. Clin Cancer Res. 2006;12(2):516–22.

    Article  CAS  PubMed  Google Scholar 

  326. Minard-Colin V, Ichante JL, Nguyen L, Paci A, Orbach D, Bergeron C, et al. Phase II study of vinorelbine and continuous low doses cyclophosphamide in children and young adults with a relapsed or refractory malignant solid tumour: good tolerance profile and efficacy in rhabdomyosarcoma—a report from the Societe Francaise des Cancers et leucemies de l’Enfant et de l’adolescent (SFCE). Eur J Cancer. 2012;48(15):2409–16.

    Article  CAS  PubMed  Google Scholar 

  327. Vats T, Buchanan G, Mehta P, Ragab A, Hvizdale E, Nitschke R, et al. A study of toxicity and comparative therapeutic efficacy of vindesine-prednisone vs. vincristine -prednisone in children with acute lymphoblastic leukemia in relapse. A Pediatric Oncology Group study. Invest New Drugs. 1992;10(3):231–4.

    Google Scholar 

  328. Casanova M, Ferrari A, Bisogno G, Merks JH, De Salvo GL, Meazza C, et al. Vinorelbine and low-dose cyclophosphamide in the treatment of pediatric sarcomas: pilot study for the upcoming European Rhabdomyosarcoma Protocol. Cancer. 2004;101(7):1664–71.

    Article  CAS  PubMed  Google Scholar 

  329. Gottschling S, Meyer S, Reinhard H, Krenn T, Graf N. First report of a vincristine dose-related Raynaud’s phenomenon in an adolescent with malignant brain tumor. J Pediatr Hematol Oncol. 2004;26(11):768–9.

    Google Scholar 

  330. Barna P. Vincristine poisoning. Pediatrics. 1980;66(1):150.

    CAS  PubMed  Google Scholar 

  331. Jairam V, Roberts KB, Yu JB. Historical trends in the use of radiation therapy for pediatric cancers: 1973–2008. Int J Radiat Oncol Biol Phys. 2013;85(3):e151–5.

    Article  PubMed  Google Scholar 

  332. McKeown SR, Hatfield P, Prestwich RJ, Shaffer RE, Taylor RE. Radiotherapy for benign disease; assessing the risk of radiation-induced cancer following exposure to intermediate dose radiation. Br J Radiol. 2015;88(1056):20150405.

    Google Scholar 

  333. Bernstein EF, Harisiadis L, Salomon GD, Harrington F, Mitchell JB, Uitto J, et al. Healing impairment of open wounds by skin irradiation. J Dermatol Surg Oncol. 1994;20(11):757–60.

    Article  CAS  PubMed  Google Scholar 

  334. Gajdusek C, Onoda K, London S, Johnson M, Morrison R, Mayberg M. Early molecular changes in irradiated aortic endothelium. J Cell Physiol. 2001;188(1):8–23.

    Article  CAS  PubMed  Google Scholar 

  335. Edwards EK Jr, Edwards EK Sr. The effect of superficial x-radiation on epidermal Langerhans cells in human skin. Int J Dermatol. 1990;29(10):731–2.

    Article  PubMed  Google Scholar 

  336. Hymes SR, Strom EA, Fife C. Radiation dermatitis: clinical presentation, pathophysiology, and treatment 2006. J Am Acad Dermatol. 2006;54(1):28–46.

    Article  PubMed  Google Scholar 

  337. Fajardo LF. The pathology of ionizing radiation as defined by morphologic patterns. Acta Oncol. 2005;44(1):13–22.

    Article  PubMed  Google Scholar 

  338. Levin WP, Kooy H, Loeffler JS, DeLaney TF. Proton beam therapy. Br J Cancer. 2005;93(8):849–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  339. Bindra RS, Wolden SL. Advances in radiation therapy in pediatric neuro-oncology. J Child Neurol. 2016;31(4):506–16.

    Article  PubMed  Google Scholar 

  340. Kun LE, Beltran C. Radiation therapy for children: evolving technologies in the era of ALARA. Pediatr Radiol. 2009;39(Suppl 1):S65–70.

    Article  PubMed  Google Scholar 

  341. Suneja G, Poorvu PD, Hill-Kayser C, Lustig RA. Acute toxicity of proton beam radiation for pediatric central nervous system malignancies. Pediatr Blood Cancer. 2013;60(9):1431–6.

    Article  PubMed  Google Scholar 

  342. Ryan JL. Ionizing radiation: the good, the bad, and the ugly. J Invest Dermatol. 2012;132(3 Pt 2):985–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  343. Hill A, Hanson M, Bogle MA, Duvic M. Severe radiation dermatitis is related to Staphylococcus aureus. Am J Clin Oncol. 2004;27(4):361–3.

    Article  PubMed  Google Scholar 

  344. Donahue B. Short- and long-term complications of radiation therapy for pediatric brain tumors. Pediatr Neurosurg. 1992;18(4):207–17.

    Article  CAS  PubMed  Google Scholar 

  345. Servodidio CA, Abramson DH. Acute and long-term effects of radiation therapy to the eye in children. Cancer Nurs. 1993;16(5):371–81.

    Article  CAS  PubMed  Google Scholar 

  346. Otmani N. Oral and maxillofacial side effects of radiation therapy on children. J Can Dent Assoc. 2007;73(3):257–61.

    PubMed  Google Scholar 

  347. Herold WCNL. Pseudoepitheliomatous reaction (pseudo recidive) following radiation therapy of epitheliomata. Acta Derm Venereol (Stockh). 1957;2:426–9.

    Google Scholar 

  348. Walter J. Epithelioma and papilloma arising on recently irradiated skin, report of three cases. Br Med J. 1950;1(4648):273, illust, pl.

    Google Scholar 

  349. Nelson LM. Self-healing pseudocancers of the skin. Calif Med. 1959;90(1):49–54.

    CAS  PubMed  PubMed Central  Google Scholar 

  350. Rieber JG, Kessel KA, Witt O, Behnisch W, Kulozik AE, Debus J, et al. Treatment tolerance of particle therapy in pediatric patients. Acta Oncol. 2015;54(7):1049–55.

    Article  CAS  PubMed  Google Scholar 

  351. Chou RH, Wong GB, Kramer JH, Wara DW, Matthay KK, Crittenden MR, et al. Toxicities of total-body irradiation for pediatric bone marrow transplantation. Int J Radiat Oncol Biol Phys. 1996;34(4):843–51.

    Article  CAS  PubMed  Google Scholar 

  352. Twardella D, Popanda O, Helmbold I, Ebbeler R, Benner A, von Fournier D, et al. Personal characteristics, therapy modalities and individual DNA repair capacity as predictive factors of acute skin toxicity in an unselected cohort of breast cancer patients receiving radiotherapy. Radiother Oncol. 2003;69(2):145–53.

    Article  CAS  PubMed  Google Scholar 

  353. Porock D, Kristjanson L, Nikoletti S, Cameron F, Pedler P. Predicting the severity of radiation skin reactions in women with breast cancer. Oncol Nurs Forum. 1998;25(6):1019–29.

    CAS  PubMed  Google Scholar 

  354. Kutler DI, Patel KR, Auerbach AD, Kennedy J, Lach FP, Sanborn E, et al. Natural history and management of Fanconi anemia patients with head and neck cancer: A 10-year follow-up. Laryngoscope. 2016;126(4):870–9.

    Article  PubMed  Google Scholar 

  355. Thomas ER, Shanley S, Walker L, Eeles R. Surveillance and treatment of malignancy in Bloom syndrome. Clin Oncol (R Coll Radiol). 2008;20(5):375–9.

    Article  CAS  Google Scholar 

  356. Pritchard J, Sandland MR, Breatnach FB, Pincott JR, Cox R, Husband P. The effects of radiation therapy for Hodgkin’s disease in a child with ataxia telangiectasia: a clinical, biological and pathologic study. Cancer. 1982;50(5):877–86.

    Article  CAS  PubMed  Google Scholar 

  357. Schaffer JV, Orlow SJ. Radiation therapy for high-risk squamous cell carcinomas in patients with xeroderma pigmentosum: report of two cases and review of the literature. Dermatology. 2011;223(2):97–103.

    Article  PubMed  Google Scholar 

  358. Morris MM, Powell SN. Irradiation in the setting of collagen vascular disease: acute and late complications. J Clin Oncol. 1997;15(7):2728–35.

    Article  CAS  PubMed  Google Scholar 

  359. De Naeyer B, De Meerleer G, Braems S, Vakaet L, Huys J. Collagen vascular diseases and radiation therapy: a critical review. Int J Radiat Oncol Biol Phys. 1999;44(5):975–80.

    Article  PubMed  Google Scholar 

  360. Ross JG, Hussey DH, Mayr NA, Davis CS. Acute and late reactions to radiation therapy in patients with collagen vascular diseases. Cancer. 1993;71(11):3744–52.

    Article  CAS  PubMed  Google Scholar 

  361. Chan RJ, Webster J, Chung B, Marquart L, Ahmed M, Garantziotis S. Prevention and treatment of acute radiation-induced skin reactions: a systematic review and meta-analysis of randomized controlled trials. BMC Cancer. 2014;14:53.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Recommended Reading

  • Andre N, Meille C. Taxanes in paediatric oncology: and now? Cancer Treatment Rev. 2006;32:65–73.

    Google Scholar 

  • Bolognia JL, Cooper DL, Glusac EJ. Toxic erythema of chemotherapy: a useful clinical term. J Am Acad Dermatol. 2008;59(3):524–9.

    Article  PubMed  Google Scholar 

  • Hymes SR, Strom EA, Fife C. Radiation dermatitis: clinical presentation, pathophysiology, and treatment 2006. J Am Acad Dermatol. 2006;54(1):28–46.

    Article  PubMed  Google Scholar 

  • Reyes-Habito CM, Roh EK. Cutaneous reactions to chemotherapeutic drugs and targeted therapies for cancer: part I. Conventional chemotherapeutic drugs. J Am Acad Dermatol. 2014;71(2):203e1–e12.

    Article  CAS  Google Scholar 

  • Ryan JL. Ionizing radiation: the good, the bad, and the ugly. J Invest Dermatol. 2012;132(3 Pt 2):985–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Shepherd GM. Hypersensitivity reactions to chemotherapeutic drugs. Clin Rev Allergy Immunol. 2003;24(3):253–6.

    Article  CAS  PubMed  Google Scholar 

  • Webber KA, Kos L, Holland KE, Margolis DA, Drolet BA. Intertriginous eruption associated with chemotherapy in pediatric patients. Arch Dermatol. 2007;143(1):67–71.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, University of California, San Francisco, 1701 Divisadero Street, 3rd Floor, Box 0316, San Francisco, CA, 94134, USA

    Lucinda L. Kohn M.H.S., M.D. & Sonal D. Shah M.D.

Authors
  1. Lucinda L. Kohn M.H.S., M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sonal D. Shah M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sonal D. Shah M.D. .

Editor information

Editors and Affiliations

  1. Harvard Medical School, Boston Children’s Hospital, Boston, Massachusetts, USA

    Jennifer T. Huang

  2. Washington University School of Medicine, St. Louis, Missouri, USA

    Carrie C. Coughlin

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this chapter

Cite this chapter

Kohn, L.L., Shah, S.D. (2018). Cutaneous Reactions to Traditional Chemotherapy and Radiation Therapy. In: Huang, J., Coughlin, C. (eds) Skin Tumors and Reactions to Cancer Therapy in Children. Springer, Cham. https://doi.org/10.1007/978-3-319-66200-8_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-66200-8_7

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-66199-5

  • Online ISBN: 978-3-319-66200-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation